Abstract
SF0166, a small-molecule αvβ3 antagonist, has physiochemical properties that allow distribution to the posterior segment of the eye after topical administration in an ophthalmic solution. The pharmacodynamics and ocular distribution of SF0166 were evaluated in several cell lines, chick chorioallantoic membrane assays, and models of ocular neovascularization in mice and pigmented rabbits. SF0166 inhibited cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. SF0166 inhibited integrin-ligand interactions at IC50 values of 0.6-13 nM for human αvβ3, αvβ6, and αvβ8 SF0166 significantly decreased neovascularization in the oxygen-induced retinopathy mouse model. SF0166 distributed to the choroid and retina after topical ocular administration in amounts that substantially exceeded the cellular IC50 for adhesion to vitronectin; drug concentrations were maintained for >12 hours. In the laser-induced choroidal neovascularization model, topical ocular administration of SF0166 decreased lesion area compared with vehicle and was comparable to a bevacizumab injection. In the vascular endothelial growth factor-induced early neovascularization and vascular leakage model, topical ocul...Continue Reading
References
Jul 27, 2001·Journal of Cellular Physiology·Y TeraiY Sato
Nov 6, 2001·Molecular and Cellular Biochemistry·R Tsou, F F Isik
Oct 3, 2002·The Biochemical Journal·Steven B LudbrookCarmel M T Horgan
Apr 23, 2003·Experimental Cell Research·M Lourdes Ponce, Hynda K Kleinman
Dec 23, 2003·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Antonella N WitmerReinier O Schlingemann
Apr 14, 2004·Archives of Ophthalmology·Nathan CongdonUNKNOWN Eye Diseases Prevalence Research Group
Feb 3, 2005·The Journal of Clinical Endocrinology and Metabolism·M G MurphyUNKNOWN L-000845704 Study Group
Nov 24, 2005·Eye·A Foster, S Resnikoff
Mar 28, 2006·Investigative Ophthalmology & Visual Science·Jennifer L Wilkinson-BerkaRichard E Gilbert
Dec 18, 2007·The Journal of Pharmacology and Experimental Therapeutics·Rosemary J SantulliBruce P Damiano
Nov 13, 2013·Nature Medicine·Neil C HendersonDean Sheppard
Aug 12, 2014·The Lancet Global Health·Rupert R A BourneUNKNOWN Vision Loss Expert Group
Jan 20, 2017·Science Translational Medicine·Raquel Lima E SilvaPeter A Campochiaro
Citations
Jul 14, 2020·Expert Opinion on Investigational Drugs·Ashay D BhatwadekarThomas Ciulla
Aug 15, 2020·AAPS PharmSciTech·Fang LiNing He
May 1, 2020·Expert Opinion on Investigational Drugs·Lincoln T ShawSeenu M Hariprasad
Sep 21, 2020·Progress in Retinal and Eye Research·Sayon Roy, Dongjoon Kim
Mar 30, 2021·Progress in Retinal and Eye Research·Inge Van HoveJean H M Feyen
May 19, 2021·Nature Communications·Kyle BattistonWendy Naimark
Sep 19, 2021·Nature Reviews. Drug Discovery·R J SlackR J D Hatley